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Abstract
An endoleak type 2 (EL2) is a relatively frequent event after an EVAR but 30–35% of EL2 
can become progressive, which can cause a loss in the important sealing zone of the stent 
graft. Diagnosis is made by three-phase CT angiogram or by contrast-enhanced duplex 
scan. EL2 should be treated if the aortic sac grows more than 5 mm in 6 months time. The 
first suitable treatment is the endovascular approach with embolization of the inferior 
mesenteric artery (IMA) or lumbar arteries. Paravertebral puncture, under CT navigation 
to embolize the lumbar artery or a part of the aortic sac with the EL2, is another alterna-
tive. If the endovascular treatment is not successful in 2–3 times, we should consider a 
surgical approach. The operative approach can be a laparoscopic or an open operation: 
the laparoscopic approach allows us to clip the IMA and lumbar arteries. The open sur-
gery involves laparotomy, ligation of the IMA, and endoaneurysmorrhaphy (suture of 
lumbar artery origins from inside) and then the suture of the aortic sac tightly around 
the stent graft in situ. The aortic occlusion balloon should be inserted below the renal 
arteries prior to open surgery. The surgical procedures have good outcomes and should 
be considered when the endovascular treatment is unsuccessful.
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1. Introduction
Endoleak type 2 (EL2) is described as a refilling of the aortic sac via branches such as lumbar 
arteries (LAs), inferior mesenteric artery (IMA), median sacral artery, or accessory renal arter-
ies after endovascular aneurysm repair (EVAR). Endoleak through the internal iliac artery 
should be classified as endoleak type 1c (Figure 1). We could imagine the EL2 as a type of 
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a false aneurysm in the thrombus around the stent-graft (SG) where we have inflow and 
outflow via sac branches.
We can distinguish certain types of EL2s:
Early—occurs within 30 days after EVAR
Late—occurs within 12 months after EVAR
Persistent—long lasting for more than 6 months
The progressive type of the EL2 causes the aortic sac to grow ≥5 mm/6 months with a risk 
of other complications. It plays an important role in the pressure gradient between the sac 
branches (mostly IMA, LAs, etc.), the position of the SG, and the pulsating volume between 
visceral branches through the sac space. It forms a cavity that clots around the SG, which has 
blood flow and causes EL2 (Figure 1) [1–4]. We have to take into account arterial hyperten-
sion and atherosclerotic changes of the aortic branches; their peripheral resistance is also 
an important factor. Visceral branches of abdominal aorta have low peripheral resistance 
physiologically, but due to atherosclerotic changes (calcifications) they lose flexibility and 
the resistance can be increased. Due to the pressure gradient between LAs and the IMA with 
artery wall calcification, EL2 can be persistent for a long time. Low flow is difficult to detect, 
Figure 1. Example of the endoleak type 2 (EL2) flowing into a sac and image of the pulsatile volume behind/around the 
stent-graft (SG) with inferior mesenteric artery inflow (red arrow) and lumbar artery outflow. The black arrow shows 
the distance between the SG and the sac wall where part of the SG can work as a piston to pump the blood as a pulsatile 
volume and keep the EL2 persistent and progressive.
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therefore it is important to provide a precise three-phase computed tomography angiogram 
(CTA). An alternative investigation is a contrast-enhanced Duplex scan (CEDS). It is well 
known that EL2 is a relatively frequent finding after EVAR in 25–30% of cases [5–11], but 
it can be resolved spontaneously (80%) [6, 9–13]. It can be persistent for a longer period of 
time without further aortic sac dilatation, but when progressive growth is accompanied by 
increasing diameter of an aneurysm, then the finding requires immediate treatment to avoid 
severe complications.
2. Diagnosis
We can obtain initial information regarding EL2 directly from the final angiogram promptly 
after EVAR; this is routine and it can show clear initial evidence of EL2. Thanks to regular 
ultrasound monitoring we can pick up enlargement of the sac diameter or detect flow in the 
sac by Doppler ultrasound scan (Figure 2). Diagnosis is mostly confirmed by three-phase 
CTA (arterial, venous, and late venous phases). An ideal alternative to providing a dynamic 
scan is CEDS (Figure 3) [14, 15]. If aortic sac growth is slow we can use an aortic angiogram to 
confirm the endoleak and at the same time we can use this approach for endovascular treat-
ment. A new method of endoleak diagnosis could be 4D magnetic resonance but this tech-
nique is not a routine method at present [16]. A CTA with good arterial and venous phases 
is the gold standard (two- or three-phase CTA) for diagnosis, and together with software 
projections can provide an image for potential treatment. Dynamic feeling of the aneurysmal 
sac can confirm the importance of a solution and explain the progressivity of the endoleak. 
Visualization of the sac collaterals and connection with the superior mesenteric artery 
(SMA), renal arteries, or other important sac arteries can be the best option for endovascular 
treatment to reach the branch for embolization. Not every EL2 is indicated for intervention. 
Figure 2. Duplex scan with color Doppler with endoleak type 2 via inferior mesenteric artery, marked by arrow.
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Characteristics, especially progressivity (growth ≥0.5 cm/6 months, ≥1 cm/1 year), play an 
important role in the decision to treat EL2 by intervention to stop its progress and avoid 
further complications.
3. Prevention of EL2
Intra-procedural embolization of IMA, LAs, and other sac branches prior to proper EVAR is 
necessary if their diameters are more than 2 mm [8, 17, 18]. Embolization of the accessory renal 
artery can inflict regional renal necrosis and a hypertension episode, therefore it must be eval-
uated individually to minimize patient risk. An individual approach has to involve consider-
ations of age, main organs, functions, and reserves together with comorbidity. The best type 
of SG is an important factor as well (it should minimize inflow into the sac through branches 
and reach the maximum of the sealing zone) to decrease EL2 formation as a sac branches flow 
connection. The endovascular aneurysm sealing technique [19] is an option to reduce flow into 
the aneurysmal sac via visceral branches. The technique used to fill the sac with a polymer can 
reduce backflow from the sac branches and their communication within the sac can decrease 
the potential formation of EL2. This technique can have side effects regarding sac and neck 
dilatation, and expansion in the sac can lead to misplacement of the SG and further complica-
tions [20]. Aneurysm sac embolization [21, 22] during the EVAR procedure using coils and 
glue can decrease the rise of endoleak, reduce sac volume, and improve its shrinkage. This 
method was described with a lower rate of reintervention due to EL2, but statistically, there 
was no clear outcome to confirm this technique as the best solution for prevention. From a 
clinical perspective, selective embolization of the sac branches with greater lumen diameters 
(≥2–3 mm) is more efficient to decrease the potential risk of EL2 formation. We can use fewer 
coils and glue together with lower irradiation time with our comparison with the sac emboli-
zation only. It is helpful to use so-called 3D fusion to navigate cannulation of the sac branches. 
Figure 3. Contrast enhanced Duplex scan of endoleak type 2 via lumbar arteries, marked by arrows.
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Stopping backflow and outflow via sac branches (to break communications between the sac 
branches, namely IMA and LAs) becomes more efficient when we compare sac embolization 
with a potential risk of formation of small roads between coils and glue mass as a restora-
tion of communication between the sac branches. The coils and glue in the sac cause further 
artifacts on CTA, and to visualize the endoleaks may be difficult and involve visibility of the 
treated EL2. High blood pressure treatment [23], statins [24], and regulation of anticoagula-
tion therapy [25] are also important parts of prevention with the possibility of decreasing the 
risk of EL2 development. The decreased pressure gradient between sac branches as described 
means that sac communication can prevent EL2 and help to reduce EL2 flow. Statins can 
stabilize sclerotic plaques and the arterial wall, which leads to rapid shrinkage of the sac after 
EVAR. Reduction of the space around the SG can minimize the flow between sac branches and 
improve contact between the SG and the sac, the so-called sealing zone.
4. Treatment
EL2 should be treated if the aortic sac grows more than 5 mm in 6 months. Conservative treat-
ment is the first method for EL2 treatment, which is occluded spontaneously in 80–90% of 
cases [26]. Conservative treatment is not the only method to watch and wait but require active 
treatment of arterial hypertension to decrease pressure gradient into the sac and sac branches. 
Statins can support the stabilization process of atherosclerotic plaque and avoid further sac 
dilatation [1, 27, 28]. Surveillance by ultrasound to measure the aneurysm diameter is an 
important method of dynamic monitoring when considering a plan for interventional treat-
ment if conservative treatment is unsuccessful and the EL2 is becoming progressive.
4.1. Endovascular
EL2 can be persistent over a long time, with a stable aneurysm diameter, but in 3–5% of cases 
it can become progressive with dilatation of the aortic sac, which can cause loss of the impor-
tant sealing zone of the SG. This process can lead to the development of endoleak type 1 and 
the higher risk of aneurysmal rupture. Enlargement of the sac size can be one of the important 
signs. The first choice for interventional treatment is the endovascular approach with emboli-
zation of the IMA or LAs. CTA can show a good connection between the SMA and IMA and 
is a suitable approach to reach the IMA through a connection with the SMA and to proceed 
with coil insertion [12]. Sometimes there can be a good connection into another sac branch 
together with the LA. Embolization of the IMA can be successful but the EL2 can remain due 
to another patent LA, which can continue with the outflow instead of the IMA. We could also 
use a technique to reach the sac by a transperitoneal approach [29]. Risks of endovascular 
treatment are the dissection of the important artery (SMA, renal artery, etc.) and embolization 
into SMA/IMA branches with intestinal ischemia. If there is an early and large EL2, which 
requires rapid solution, we can try to reach the sac by the endovascular technique behind the 
SG because the SG is not fully adherent (the connection between the SG and the arterial wall 
is not rigid). This way provides an embolization of LAs or other important branches directly 
from the sac, respectively from the pulsating volume in the thrombus around the SG. We 
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can use this technique as well if there is a combination of EL2 with endoleak 1b (distal end 
of the SG endoleak) or 3b (the SG limbs are disconnected) to complete the endoleak treat-
ment. Another approach to endovascular treatment can be a paravertebral puncture of the 
aneurysm sac under CT navigation to provide embolization of a biological/histoacryl glue 
alone or with a combination of coils to embolize the LA origins and the part of the aortic sac 
with the endoleak flow where the main route of endoleak refilling can be halted [30]. We can 
use a peritoneal approach to reach the sac and provide the embolization [31]. Consistency 
and adherence of the glue are important characteristics, which play a role in the outcome 
and ensure the right place for installation. The disadvantage is the rigidity and relatively fast 
adherence of the glue, which is contrary to our aim of filling the whole volume of the EL2 
around the SG or reducing the flow as much as possible, which leads to spontaneous occlu-
sion. The post-procedure portion of the glue in the sac causes certain artifacts in the CTA, 
which could cover small EL2s. Gelatin foam and alcohol as sclerosing agents are not often 
used due to their reduced efficiency and potential risk of complications (namely, peripheral 
embolization). The main risk is infection of the SG (a severe life-threatening complication) 
and bleeding from the sac area, therefore constant repetition of this technique is not recom-
mended. If endovascular treatment is not successful after two to three attempts we should 
consider a surgical approach. Indications for operation must be considered precisely due to 
important patient background, therefore pre-assessment involving function tests such as spi-
rometry and stress ECHO together with Duplex scan of carotid arteries have become standard 
procedures before any open or laparoscopic intervention.
4.2. Laparoscopic treatment
The operative approach can be a laparoscopic or open operation. The laparoscopic approach 
is indicated for patients where the pneumoperitoneum is not contraindicated. This approach 
allows us to clip the IMA close to the sac and an initial CTA should guide us to the reachable 
segment of the IMA to avoid duodenum injury. Thanks to a camera (angulated optic) the 
laparoscopic procedure allows very good visibility of the LAs for clipping [32, 33]. The left 
side of the aorta and aneurysm is easily approached but the right side is difficult to access 
due to the tight, adherent position of the inferior vena cava. The retroperitoneal approach 
with the same endoscopic technique is a very suitable alternative, which requires a good 
overview from each side to reach the LAs for clipping; however, for the IMA it is important to 
have a clear standard laparoscopic approach to combine these techniques. The retroperitoneal 
endoscopic approach is the same as thelumbar sympathectomy approach. The laparoscopic 
approach is relatively safe. When an approach from the right side of the aorta is too risky, then 
we can clip and stop the flow in one of the side LAs to stop the EL2 because we can reduce 
the inflow or outflow with good results. We have to check the efficiency of our procedure by 
CEDS or by a table angiogram. With the results, we can evaluate our efficiency at the same 
time and conclude if our procedure has been successful. It is the opinion of the author that 
CEDS is the best combination to detect the EL2 preoperatively and guide us to find the main 
blood vessels to fix it. Only deflation and inflation of the operation space is time consuming, 
especially when the scan has to be repeated a few times. The main risk to endoscopic treat-
ment involves peritoneal and retroperitoneal bleeding but the incidence is small [32, 33].
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4.3. Open transperitoneal approach
Open surgery involves laparotomy and ligation of the IMA (Figure 4). The main approach is 
transperitoneal, which is exposure of the retroperitoneal space and aortic sac involving the 
neck of an aneurysm and aortic bifurcation. The important part is preparing the small space 
from both sides of the neck for an emergency aortic clamp or compression above the planned 
sac incision. A very good alternative is to have an occlusion balloon in the aorta close to the 
origin of the renal arteries to be ready for the eventual leak from the neck area. The main step 
of the procedure is an incision of the aortic sac and endoaneurysmorrhaphy (suture of LA 
origins from inside the sac), then the suture of the aortic sac is tightened (in two layers is a 
good option) around the SG in situ [34, 35] (Figures 5 and 6). It is very important to protect 
the SG against a misplacement. Protection involves keeping the distance from the neck area 
at around 5 cm below and not opening an aneurysm too close to the neck because there is a 
risk of losing a proximal sealing zone. To protect the position of the SG it should be kept very 
close to the dorsal wall, respectively the spine column when we are removing the thrombus 
around the SG. The moderate pressure applied to the SG against the dorsal wall will help keep 
the SG in position and decrease back bleed from the LAs. The aortic occlusion balloon, which 
Figure 4. Computed tomography angiogram of the persistent endoleak type 2 via lumbar arteries after paravertebral 
puncture of the sac and unsuccessful glue instillation/embolization.
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should be inserted below the renal arteries prior to open surgery to provide aortic occlusion 
in case of bleeding, is a better option than aortic clamping of the neck area with a risk of 
aortic wall injury. In case of bleeding it is important to suture the SG in position and provide 
a package by the aortic sac rather than to explant the SG and replace the whole SG. This 
type of the operation has severe complications, namely high lethality for patients (initially not 
suitable for any open abdominal aortic aneurysm (AAA) repair primarily) [30]. Postoperative 
high dependency unit/intensive care unit monitoring is important to check blood pressure 
but mostly uneventful laparoscopic/open procedures are well tolerated because blood loss 
is minimal and blood transfusion is not required. Fast recovery is due to an operation with-
out any aortic clamp. Mostly, the patient can be discharged within 2–5 days. There is a clear 
advantage of laparoscopy versus laparotomy because the minimally invasive approach does 
not cause paralytic ileus and small wounds are well tolerated, therefore to discharge a patient 
within 2 days is manageable without high risks. To check the efficiency of surgical treatment 
by CTA is recommended within 7–10 days and thereafter standard post-EVAR monitoring can 
be performed (Figure 7). We should wait for 1–3 months for complete occlusion of the EL2, 
Figure 6. Dual layer suture of the aortic sac after endoaneurysmorrhaphy.
Figure 5. Open sac view with stent-graft in situ after thrombus removal and suture of lumbar artery origins.
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especially when stopping only one side LAs together with IMA flow. Shrinkage of the sac can 
be clearly visible later on within a few months. CEDS is a good choice to reduce the number 
of CTAs and contrast solutions.
5. Discussion
EL2 may be a relatively passive diagnosis, and may be active only for a short period of time, 
but if there is significant growth, then it will become a potential problem with risks such as 
rupture. It is well known that the risk of rupture is relatively low but we have to continue 
with treatment to avoid refilling of the aortic sac, especially when we have a good position for 
the SG without sac dilatation, which can lead to loss of sealing zones. The advantage is that 
progressive EL2 is not as aggressive as endoleak type 1 and we should have enough time to 
plan the best strategy for treatment. EL2 remains the important diagnosis, which requires pre-
cise monitoring and appropriate investigation as well as an individual plan for each patient 
involving conservative, laparoscopic, or open surgical treatment. Dynamic filling of the sac in 
an EL2 directly after SG deployment can predict the future of EL2 but we have to evaluate a 
number of factors, which play a role in the persistence and progressivity of EL2 [17].
These factors are:
• Systolic and diastolic blood pressure
• Peripheral resistance and calcification of the sac branches (its origins)
• Position of the SG
Figure 7. Computed tomography angiogram after endoaneurysmorrhaphy without endoleak type 2 and the stent-graft 
tightly covered by the sutured sac in two layers.
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• Volume of a pulsatile cavity with arterial blood flow (in the sac and around the SG)
• Anticoagulation/antiaggregation therapy
• Numbers and diameters of patent LAs [36]
• Diameter of IMA [36]
• Warfarin [25]
Intra-operative predictors of the EL2 diameter of IMA and position of LAs play important 
roles as predictive factors of EL2, together with the diameter of the visceral branches (origins), 
their calcifications, and pressure gradients. The flow between aortic visceral branches is simi-
lar to the arteriovenous fistula. Pulsation cavity around the SG involving the origin of LAs or 
IMA, where the SG can work as a piston to pump blood between the LAs or IMA and another 
LA, respectively the sac branches. This physical mechanism can keep the patency of the EL2 
and increase pressure in the sac, which can be a reason for the progressivity of the EL2 with 
growth of the sac. It is thought that 3D printing of the endoleaks as a real model of the CTA 
with important details could provide an ideal view of the pathology and a realistic overview 
of the best method for treatment. Anatomical risks regarding potential EL2s as accessory 
renal arteries, diameter, and position of LAs should also be considered. It is believed that the 
position of the SG plays an important role when we consider the pulsation cavity between the 
SG and the dorsal aneurysmal wall. Pulsation mass due to EL2 and SG pulsation can both 
work as a pump because visceral aortic branches have low peripheral resistance and could 
help to keep the EL2 persistent and growing (Figure 1). The pulsation cavity can potentiate 
the pressure gradient between LAs and between IMA and LAs as well, therefore systemic 
blood pressure and aortic branch calcifications (blood vessel rigidity) can play an important 
role regarding patency and endoleak flow. When the SG is close to LA origins its sealing effect 
can reduce the incidence of EL2 because a potential volume of EL2 is reduced. Slow progres-
sion of the sac dilatation due to EL2 can give us useful time to arrange our strategy of treat-
ment. Monitoring is very important to check progression. Prevention involves selective 
embolization of the aneurysmal sac branches or use of the special type of SG as described for 
endovascular aneurysm sealing [19, 37]; however, together all effects of the device involve 
complications (endoleaks, SG misplacement). The preventive embolization of the sac patent 
branches (LAs, IMA, etc.), which can contribute to formation of EL2, leads to a reduction in 
EL2 incidence. When we compare the preventive sac embolization only (coils + glue) with 
selective sac branch embolization we can confirm that the selective approach is more efficient 
and has fewer artifacts and embolization materials. When we compare longer clinical out-
comes, we can confirm there is no statistical evidence that sac preventive embolization has 
long-term efficiency as a technique to prevent EL2 [21, 22]. It is recommended to embolize 
IMA and LA before SG deployment when the lumen diameter is more than 2–3 mm or if the 
number of patent LAs is more than 3. The role can play a distance between origins of LA as 
well because their flow communication is with higher predisposition. Conservative treatment 
involves blood pressure treatment, statins, and the possibility of reducing antiplatelet or anti-
coagulation therapy for a short period to support spontaneous sealing of the EL2 together 
with shrinkage of the sac. We should consider timing for future plans if conservative treat-
ment does not give results when ultrasound and three-phase CTA are used. The possibility of 
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treatment involves endovascular and surgical treatment. Minimally invasive surgical tech-
niques are a safe option with good results. If endovascular treatment is not successful, then 
we can proceed with a laparoscopic approach to clip LAs and the IMA. The retroperitoneal 
approach reaches both sides of the aortic sac with good visibility of the LA origins. If the main 
body of the SG is too far from the dorsal aortic wall and there is a relatively large space behind 
the SG (such as a pulsatile volume), then we can consider an open approach with endoaneu-
rysmorraphy to stabilize the SG position and minimize the space around the SG. The preas-
sessment of any intervention, especially the surgical one, should involve patient fitness, 
reserves, and risks in the context of patient comorbidities. Patient quality of life is an impor-
tant point in our decision to treat progressive EL2. The standard monitoring plan can be 
within 3–6 months in the first year after reintervention and then every half year or at 1-year 
intervals, eventually becoming more frequent as an individual plan due to potential restora-
tion or previous high progressivity of EL2. We should consider a fresh CTA or a new method 
of scanning such as 4D magnetic resonance angiography [16], or maybe an angiogram with 
the possibility of endovascular reintervention. The importance of diagnosis and treatment of 
EL2 is to investigate hemodynamic characters of the EL2 to consider an individual plan and 
watch the dynamic changes in time to consider the timing of intervention. When renal func-
tions are borderline and with a view to quicker progression, it would be better to prevent 
further sac growth due to EL2 and find a reason for quicker treatment to avoid issues of 
providing endovascular or surgical treatment. EL2 is not as aggressive as the endoleak type 1 
and 60–80% of cases can be treated conservatively. The residual numbers of patients with the 
progressive type of EL2 require an intervention to avoid severe complications. Endovascular 
treatment is the first step in progressive EL2. It has good efficiency and the possibility of 
repeating the intervention. The laparoscopic procedure of clipping IMA and LAs is a rela-
tively safe option from peritoneal or retroperitoneal points of view with good results, and is 
a minimally invasive approach, which indicates the best individual treatment for each patient 
to prevent complications after EVAR. Open endoaneurysmorrhaphy [34, 35] is another treat-
ment for patients where the previously described treatment is not successful and there are 
difficulties using a laparoscopic method. The risks are low where the patient is relatively fit 
for the intervention and an experienced team can prevent misplacement of the SG to mini-
mize blood loss without an aortic clamp. Explantation of the SG is not recommended because 
it is a very dangerous technique with very high lethality [30]. Haq IU et al. presented their 
results regarding the incidence and treatment of EL2 [6]. They describe 386 patients over 
10 years with a 21% (81 patients) incidence of EL2, which was treated in 65% (53 patients) 
conservatively and in 35% (28 patients) by intervention, in addition to 60% (17 patients) endo-
vascularly and 40% (11 patients) transarterially. They concluded that the incidence of pro-
gressive EL2 could be represented by an aggressive phenotype. Kumar et al. presented a 
cohort of 693 patients (2009–2013) with EVAR [38]. The team treated 225 patients due to EL2. 
The mean follow-up was 2 years. One hundred and thirty-three patients were resolved spon-
taneously, 37 were unresolved and untreated, 16 underwent an intervention, 3 had a AAA 
rupture due to EL2, and 2 patients were in the absence of the sac expansion ≥5 mm/6 months. 
The late type of EL2 occurred in 117 patients, of which 26 had sac expansion. They concluded 
that age and smoking were significant independent predictive factors for non-survival. They 
described the rupture of two patients after EVAR without sac enlargement ≥5 mm. Ultee and 
his colleagues described in a systematic review that the persistence of EL2 could be 
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accompanied by risk of rupture without an extensive growth up to 1.8% [12]. This is not com-
mon and very probably depends on the pressure in the sac and aortic wall, respectively sac 
wall endurance, where Laplace’s principle explains the pathology (Figure 8). Statins are 
described as an important part of post-EVAR treatment to support sac shrinkage and decrease 
the incidence of endoleaks involving EL2. The theory is that the effect of statins helps to sta-
bilize the arterial wall with atherosclerotic changes. The authors presented the shrinkage of 
an aneurysm within 12 and 24 months [1, 27, 28]. With the results we can expect to prevent 
endoleaks by prolonged statin administration together with a low-fat diet and regular control 
of serum lipids and lipoproteins. Patients using warfarin can have a higher predisposition for 
persistent or progressive EL2 [25]. We should consider omitting warfarin for a short period or 
using another type of anticoagulation (LMFW) if there are no further risks regarding their 
initial indication (ischemic heart disease, AF, DVT, PE, etc.). Another author suggested that 
antiplatelets such as salicylates and clopidogrel do not increase the risk of endoleaks after 
EVAR [39].
6. Conclusion
EL2 is a relatively non-aggressive diagnosis after EVAR but its growth can lead to severe 
complications. Monitoring keeps the situation under control and diagnoses the progression 
over time so that a strategy can be implemented when progressive EL2 requires treatment. We 
can summarize the clear process regarding progressive EL2 as follows [40–42].
Prevention:
Embolization of the large abdominal infra-aortic visceral branches prior to SG deployment.
Figure 8. Laplace’s law is described as tension (T) of the aneurysm wall, which is relative to pressure (P) in an aneurysm 
and the radius (r) of an aneurysm, T = P × r.
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Diagnosis:
Duplex scan (measurement of sac growth), contrast-enhanced Duplex scan, and three-phase 
CTA.
Treatment:
• Conservative (endoleak without extensive sac growth).
• Endovascular with embolization of IMA and reachable aortic sac branches.
Surgical:
• laparoscopic clipping of IMA and LA.
• endoaneurysmorrhaphy and a tight suture around the SG.
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